Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.

Trial Details

NCT ID
NCT06594939
Phase
PHASE2
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Polatuzumab Vedotin
  • Mosunetuzumab
  • Cyclophosphamide
  • Doxorubicin
  • Prednisone
  • Pegfilgrastim
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Patients aged 70-74 who are determined to be unfit or frail by the Cumulative Illness Rating Scale-Geriatric (CIRS-G) score with 5-8 comorbid condi…
  • Newly diagnosed, untreated, biopsy-proven CD20 positive diffuse large B-cell lymphoma (DLBCL) (including high-grade B-cell lymphoma and T-cell/hist…
  • a. Short-course prednisone or equivalent steroid for symptom management is allowable for up to seven days.
  • Measurable disease by positron emission tomography (PET) / computed tomography (CT) using the Lugano criteria (lymph node \>1.5 cm or extranodal si…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →